Antidepressant compliance in a rural setting: Response.

Indian J Psychiatry

Department of Psychopharmacology, National Institute of Mental Health and Neurosciences, Bengaluru, Karnataka, India. E-mail:

Published: January 2018

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5914248PMC
http://dx.doi.org/10.4103/psychiatry.IndianJPsychiatry_138_18DOI Listing

Publication Analysis

Top Keywords

antidepressant compliance
4
compliance rural
4
rural setting
4
setting response
4
antidepressant
1
rural
1
setting
1
response
1

Similar Publications

Complex regional pain syndrome (CRPS) is a chronic pain disorder characterized by severe, disproportionate pain relative to an inciting event. The disorder's pathophysiology is complex, involving both central and peripheral nervous system alterations, alongside genetic, inflammatory, and psychological factors. Using data from TriNetX, this study investigated the impact of analgesic and adjuvant therapies on psychiatric outcomes in CRPS patients.

View Article and Find Full Text PDF

Aripiprazole (ARI) is an atypical antipsychotic which is a substrate of P-glycoprotein (P-gp), a transmembrane glycoprotein that plays a crucial role in eliminating potentially harmful compounds from the organism. ARI once-monthly (AOM) is a long-acting injectable form which improves treatment compliance. Genetic polymorphisms in ABCB1 may lead to changes in P-gp function, leading to individual differences in drug disposition.

View Article and Find Full Text PDF

Introduction: Mental disorders, such as anxiety and depression, significantly impacted global populations in 2019 and 2020, with COVID-19 causing a surge in prevalence. They affect 13.4% of the people worldwide, and 21% of Iranians have experienced them.

View Article and Find Full Text PDF

Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with bipolar I disorder in the United States.

J Manag Care Spec Pharm

January 2025

Global Value and Real-World Evidence, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ.

Background: Bipolar disorder is a severe recurrent, episodic psychiatric condition with a worldwide prevalence of approximately 1%, affecting more than 5 million adults in the United States in 2020. A subtype, bipolar I disorder (BP-I), which accounts for approximately one-quarter of cases, is associated with impairments in psychosocial functioning and quality of life. Recommended treatment options include daily oral, or long-acting injectable, antipsychotics, including the aripiprazole once every month formulation, which has been shown to improve adherence compared with oral treatments.

View Article and Find Full Text PDF

Budget impact of aripiprazole once every 2 months long-acting injectable for adult patients with schizophrenia in the United States.

J Manag Care Spec Pharm

January 2025

Global Value and Real-World Evidence, Otsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ.

Background: Schizophrenia is a chronic psychiatric disorder, affecting 1.1% of the adult population in 2020 in the United States. Antipsychotic treatment is commonly used in schizophrenia management to help reduce the likelihood of symptom recurrence and relapse.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!